TAP Pharmaceutical to settle claims, pay $150 million

TAP Pharmaceutical Products agreed to settle claims that consumers and private insurers overpaid for the LHRH hormone analog leuprolide acetate (Lupron), according to a report in The Boston Globe.

Related Content:

Drug Therapy

Pivotal data for lumasiran in PH1 published in NEJM

Nedosiran explored in primary hyperoxaluria type 3

Enrollment completed in pivotal trial of nedosiran for hyperoxaluria